{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:56:05Z","timestamp":1760298965624,"version":"3.44.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ygyno.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T19:30:14Z","timestamp":1405107014000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"135","clinical-trial-number":[{"clinical-trial-number":"nct00770536","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01281254","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Charles H.","family":"Pippitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan N.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Scudder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Kridelka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumitra","family":"Ananda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuwan","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Melara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Litten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Adewoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.07.003_bb0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/CAD.0b013e32802623fc","article-title":"Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer","volume":"18","author":"Mar\u00eda Eva","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/CMAR.S15558","article-title":"Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer","volume":"3","author":"Markman","year":"2011","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2014.07.003_bb0045","article-title":"Final overall survival (OS) results from AURELIA, an open-label randomized phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)","volume":"49","author":"Witteveen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s10637-013-0011-3","article-title":"Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I\/II study of the AGO study group (AGO-OVAR 2.13)","volume":"31","author":"Harter","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0092-8674(00)81813-9","article-title":"Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis","volume":"87","author":"Suri","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.yexcr.2005.09.002","article-title":"Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling","volume":"312","author":"Eklund","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0075","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1\/2-neutralizing peptibody","volume":"9","author":"Coxon","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0080","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1200\/JCO.2008.19.6683","article-title":"Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors","volume":"27","author":"Herbst","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2014.07.003_bb0090","article-title":"A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1","volume":"49","author":"Monk","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000088959","article-title":"Topotecan in platinum-resistant epithelial ovarian cancer","volume":"51","author":"Karabulut","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0105","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2008.02.028","article-title":"Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers","volume":"109","author":"Morris","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2010.02.008","article-title":"Identification and inhibition of drug target interference in immunogenicity assays","volume":"355","author":"Zhong","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0125","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2010-0947","article-title":"Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer","volume":"95","author":"Bass","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0130","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0135","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00024669-200605050-00005","article-title":"Management strategies for partially platinum-sensitive ovarian cancer","volume":"5","author":"Ledermann","year":"2006","journal-title":"Am J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2011.08.033","article-title":"Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier Oncology Group","volume":"123","author":"Ramasubbaiah","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0155","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mds172","article-title":"Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A","article-title":"Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome","volume":"91","author":"Safra","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0165","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2010.11.008","article-title":"A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group study (GOG 146Q)","volume":"120","author":"Herzog","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0170","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1002\/cncr.27632","article-title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"118","author":"Rini","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mds502","article-title":"Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer","volume":"24","author":"Eatock","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0180","series-title":"European Cancer Congress 2013; Sep 27\u2013Oct 1; Amsterdam, Netherlands","article-title":"A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1","author":"Monk","year":"2013"},{"issue":"Suppl. 9","key":"10.1016\/j.ygyno.2014.07.003_bb0185","article-title":"A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery","volume":"23","author":"Vergote","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/bjc.2012.594","article-title":"A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma","volume":"108","author":"Peeters","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.003_bb0195","doi-asserted-by":"crossref","first-page":"975PD","DOI":"10.1016\/S0923-7534(20)33578-X","article-title":"A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery","volume":"23","author":"Vergote","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl. 9","key":"10.1016\/j.ygyno.2014.07.003_bb0200","first-page":"LBA26","article-title":"Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP)\u00b1bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG Aurelia randomized phase III trial","volume":"23","author":"Poveda","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:35:57Z","timestamp":1758771357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814010786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0090825814010786"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}